natgillin/translations-raw huggingface dataset:
Flushing events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience flushing, these events may continue to occur intermittently throughout treatment with Tecfidera.
Prebavni dogodki so se pojavili na začetku zdravljenja (v glavnem so se pojavili v prvem mesecu), pri čemer se lahko pri bolnikih, pri katerih se pojavijo prebavni dogodki, ti dogodki občasno pojavljajo ves čas zdravljenja z zdravilom Tecfidera.
In clinical trials, 34% of Tecfidera treated patients experienced flushing.
V kliničnih preskušanjih je 34 % bolnikov, zdravljenih z zdravilom Tecfidera, doživelo vročinsko oblivanje, pri večini bolnikov je bilo blago ali zmerno.
Each gastro-resistant hard capsule contains 240 mg dimethyl fumarate
Ena gastrorezistentna trda kapsula vsebuje 240 mg dimetilfumarata.
Tecfidera 120 mg gastro-resistant hard capsules Tecfidera 240 mg gastro-resistant hard capsules
Tecfidera 120 mg gastrorezistentne trde kapsule Tecfidera 240 mg gastrorezistentne trde kapsule
Increase of liver enzymes and cases of drug-induced liver injury (elevations in transaminases ≥3 times ULN with concomitant elevations in total bilirubin >2 times ULN), have been reported in post marketing experience following Tecfidera administration, which resolved upon treatment discontinuation.
Po uporabi zdravila Tecfidera so pri izkušnjah v obdobju trženja poročali o zvišanju jetrnih encimov in primerih z zdravilom povzročene okvare jeter (zvišanje transaminaz na ≥ 3-kratno ULN s sočasnim zvišanjem celotnega bilirubina na > 2-kratno ULN).
Side effects which may show up in your blood or urine tests low levels of white blood cells (lymphopenia, leucopenia) in the blood.
- nizke ravni belih krvničk (limfopenija, levkopenija) v krvi.
Common White blood cell count decreased Common 1 Adverse reactions derived only during post marketing experience
1Neželeni učinki, ugotovljeni samo pri izkušnjah iz obdobja trženja.
Oral administration of dimethyl fumarate at 25, 100, and 250 mg/kg/day to rats during pregnancy and lactation resulted in lower body weights in the F1 offspring, and delays in sexual maturation in F1 males at 11 times the recommended dose on an AUC basis.
Peroralno dajanje dimetilfumarata pri odmerku 25, 100 in 250 mg/kg/dan podganam med brejostjo in laktacijo je pri 11-kratniku priporočenega odmerka na podlagi AUC povzročilo nižjo telesno maso F1 potomcev in zapoznelo spolno zrelost F1 samcev.
Cases of herpes zoster have occurred with Tecfidera.
V povezavi z zdravilom Tecfidera so se pojavili primeri herpesa zostra.
The forestomach in rodents does not have a human counterpart.
Za predželodec pri glodavcih pri ljudeh ni ustreznega organa.
Nervous system disorders
- prebavne motnje
Tecfidera 120mg gastro-resistant hard capsules Each gastro-resistant hard capsule contains 120 mg dimethyl fumarate.
Tecfidera 120 mg gastrorezistentne trde kapsule Ena gastrorezistentna trda kapsula vsebuje 120 mg dimetilfumarata.
Starting dose 120 mg twice a day.
120 mg dvakrat na dan.
Elevations in transaminases ≥3 times ULN with concomitant elevations in total bilirubin >2 times ULN, were not observed in placebo-controlled studies.
Zvišanja transaminaz na ≥ 3-kratno ULN s sočasnim zvišanjem celotnega bilirubina na > 2
Since the renal pathway is a secondary route of elimination for dimethyl fumarate accounting for less than 16% of the dose administered, evaluation of pharmacokinetics in individuals with renal impairment was not conducted.
16 % uporabljenega odmerka, ocene farmakokinetike pri posameznikih z okvaro ledvic niso izvedli.
Severe renal and hepatic impairment
Huda okvara ledvic in jeter
Potential risks associated with acetylsalicylic acid therapy should be considered prior to co-administration with Tecfidera in patients with Relapsing Remitting MS. Long term (> 4 weeks) continuous use of acetylsalicylic acid has not been studied (see sections 4.4 and 4.8).
Dolgotrajne (> 4 tednov) neprekinjene uporabe acetilsalicilne kisline niso raziskovali (glejte poglavji 4.4 in 4.8).
Nonclinical studies in rodent, rabbits, and monkeys were conducted with a dimethyl fumarate suspension (dimethyl fumarate in 0.8% hydroxypropyl methylcellulose) administered by oral gavage.
Toksikologija Z dimetilfumaratom v obliki suspenzije (dimetilfumaratom v 0,8 % hidroksipropil metilcelulozi) so izvedli predklinične študije pri glodavcih, kuncih in opicah, ki so jim suspenzijo dajali s peroralno gavažo.
Tecfidera 240mg gastro-resistant hard capsules
Tecfidera 240 mg gastrorezistentne trde kapsule
In the MRI cohort 36% of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions 1.4).
lezije Gd+ ob izhodišču (povprečno število lezij Gd+ 1,4).
Taking into account the PRAC Assessment Report on the PSUR(s) for dimethyl fumarate (multiple sclerosis), the scientific conclusions of CHMP are as follows:
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za dimetilfumarat (multipla skleroza) je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke: Pri nobenem primeru niso izrecno poročali o Fanconijevem sindromu pri indikaciji multiple skleroze
The incidence of the adverse reactions below are expressed according to the following categories:
Zaradi zasnove študije je bila zelo aktivna bolezen opredeljena kot sledi:
Hypoxia1
neznana hipoksija1
Gastrointestinal disorders
- vnetje črevesne obloge (gastroenteritis)
Each gastro-resistant hard capsule contains 120 mg dimethyl fumarate
Ena gastrorezistentna trda kapsula vsebuje 120 mg dimetilfumarata.
How to store Tecfidera
Shranjevanje zdravila Tecfidera
Effects on the immune system In preclinical and clinical studies, dimethyl fumarate demonstrated anti-inflammatory and immunomodulatory properties.
Dimetilfumarat je v predkliničnih in kliničnih študijah pokazal protivnetne in imunomodulacijske lastnosti.
Tecfidera 120 mg gastro-resistant hard capsules dimethyl fumarate
Tecfidera 120 mg gastrorezistentne trde kapsule dimetilfumarat
Tecfidera was evaluated in a prospective open-label, uncontrolled study in 22 paediatric patients with
Zdravilo Tecfidera so ocenili v prospektivni odprti nekontrolirani študiji pri 22 pediatričnih bolnikih z RRMS, starih od 13 do 17 let (4 bolniki so bili stari ≤14 let) .
Tecfidera 120mg gastro-resistant hard capsules
Tecfidera 120 mg gastrorezistentne trde kapsule
The benefit of breast-feeding for the child and the benefit of therapy for the woman should be taken into account.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Tecfidera, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Croscarmellose sodium
Število limfocitov
Blood and lymphatic system disorders
Bolezni krvi in limfatičnega sistema limfopenija pogosti levkopenija pogosti trombocitopenija občasni
In Study 2, patients had the following median baseline characteristics: age 37 years, disease duration 6.0 years, EDSS score 2.5.
V študiji 2 so imeli bolniki naslednje mediane vrednosti za izhodiščne karakteristike: starost 37 let,
Talk to your doctor before taking Tecfidera if you have: - severe kidney disease - severe liver disease - a disease of the stomach or bowel - a serious infection (such as pneumonia)
- hudo bolezen ledvic, - hudo bolezen jeter, - bolezen želodca ali črevesja,
Tecfidera 240 mg gastro-resistant hard capsules dimethyl fumarate
Tecfidera 240 mg gastrorezistentne trde kapsule dimetilfumarat
These may affect up to 1 in 10 people: - inflammation of the lining of the intestines (gastroenteritis) - being sick (vomiting) - indigestion (dyspepsia) - inflammation of the lining of the stomach (gastritis) - gastrointestinal disorder - burning sensation - hot flush, feeling hot - itchy skin (pruritus) - rash - pink or red blotches on the skin (erythema)
- pekoč občutek - vročinski oblivi, občutek vročine - srbeča koža (pruritus) - izpuščaj - rožnate ali rdeče lise na koži (eritem)
You should inform your doctor immediately if you suspect you have any symptoms of shingles.
Če sumite, da imate kakršne koli simptome pasovca, o tem takoj obvestite zdravnika.
Renal tubular hyperplasia was observed in rats with life time dosing (2-year study).
Pri podganah so pri vseživljenjskem dajanju opazili hiperplazijo ledvičnih tubulov
Dyspnoea1
neznana dispneja1
Package leaflet: Information for the patient Tecfidera 120 mg gastro-resistant hard capsules Tecfidera 240 mg gastro-resistant hard capsules dimethyl fumarate
Tecfidera 120 mg gastrorezistentne trde kapsule Tecfidera 240 mg gastrorezistentne trde kapsule dimetilfumarat (dimethylis fumaras)
Tecfidera 240mg gastro-resistant hard capsules Each gastro-resistant hard capsule contains 240 mg dimethyl fumarate For the full list of excipients, see section 6.1.
Tecfidera 240 mg gastrorezistentne trde kapsule Ena gastrorezistentna trda kapsula vsebuje 240 mg dimetilfumarata.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS HEAT SEALED BLISTER CARD
Splošne težave in spremembe na mestu aplikacije občutek vročine pogosti
In the MRI cohort 45% of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions 2.4).
lezije Gd+ ob izhodišču (povprečno število lezij Gd+ 2,4).
Progressive Multifocal Leukoencephalopathy (PML)
Progresivna multifokalna levkoencefalopatija (PML) V primeru zmerne do hude dolgotrajne limfopenije so se pri uporabi dimetilfumarata in drugih zdravil,
Dimethyl fumarate is not quantifiable in plasma following oral administration of Tecfidera.
Po peroralni uporabi zdravila Tecfidera dimetilfumarata v plazmi ni mogoče določiti.
Gelatin
ČET
Hepatic impairment
Klinični opazovani dogodkia
Sat.
odmerka.
Capsule shell
Delovanje jeter
There was no case explicitly reporting Fanconi syndrome in the Multiple Sclerosis (MS) indication; however, it has been reported in literature that that female patients with psoriasis treated long-term with fumaric acid esters seem to be at particular risk.
(MS), vendar pa literatura navaja, da so bolnice s psoriazo, ki se dolgotrajno zdravijo z estri fumarne kisline, izpostavljene izrazitejšemu tveganju.
Within 1 month, the recommended maintenance dose of 240 mg twice a day should be resumed.
V 1 mesecu je treba ponovno preiti na priporočeni vzdrževalni odmerek
Pregnancy and breast-feeding
- bruhanje - slaba prebava (dispepsija)
Key elements to be included in the educational material:
Ključni elementi, ki morajo biti vključeni v izobraževalnem gradivu:
• Acute coronary syndrome (including myocardial infarction) within the last 30 days
• Akutni koronarni sindrom (vključno z miokardnim infarktom) v zadnjih 30 dneh.
The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented:
Države članice morajo zagotoviti, da so vsi pogoji ali omejitve v zvezi z varno in učinkovito uporabo zdravila, opisani spodaj, implementirani:
The number of vials of BRINAVESS concentrate required to prepare the appropriate quantity of solution for the treatment of an individual patient will depend on the patient's weight, and the vial size.
Število vial s koncentratom zdravila BRINAVESS, potrebnih za pripravo ustrezne količine raztopine za zdravljenje posameznega bolnika, je odvisno od mase bolnika in velikosti viale.
Appropriate measures to manage and minimize the risks, including the need for close monitoring during and after administration of BRINAVESS.
Ustrezni ukrepi za obvladovanje in zmanjševanje tveganja, vključno s potrebo po natančnem nadzorovanju med uporabo zdravila BRINAVESS in po njej.
Patient selection criteria, including contraindications, special warnings and precautions for use and information about patient populations with limited information from clinical trials.
Kriteriji za izbiro bolnika, vključno s kontraindikacijami, posebnimi opozorili in previdnostnimi ukrepi ter podatki o populacijah bolnikov, za katere je na voljo malo podatkov iz kliničnih študij.
The Marketing Authorisation Holder shall ensure that all Healthcare Professionals (HCP) involved in the administration of BRINAVESS are provided with a healthcare professional information pack containing the following:
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da vsi zdravstveni delavci, vključeni pri uporabi zdravila BRINAVESS, dobijo paket z informacijami za zdravstveno osebje, ki vsebuje naslednje:
Educational material for Healthcare Professionals Summary of Product Characteristics, Package Leaflet and Labelling
Izobraževalno gradivo za zdravstveno osebje Povzetek glavnih značilnosti zdravila, navodilo za uporabo, ovojnina
• Patients with severe aortic stenosis, patients with systolic blood pressure <100 mm Hg, and patients with heart failure class NYHA III and NYHA IV.
• Bolniki s hudo aortno stenozo, bolniki s sistoličnim krvnim tlakom < 100 mm Hg in bolniki s srčnim popuščanjem v razredu NYHA III ali NYHA IV.
Risk of atrial flutter may be increased in patients receiving class I AADs.
Tveganje za atrijsko undulacijo je lahko pri bolnikih, ki prejemajo antiaritmike skupine I, povečano.
BRINAVESS may be available in different vial sizes [available vial sizes to be inserted locally].
Zdravilo BRINAVESS je lahko na voljo v vialah različnih velikosti [velikosti vial, ki so na voljo, vstavi država članica].
Only a well-qualified healthcare professional should administer BRINAVESS and should frequently monitor the patient for the duration of the infusion and for at least 15 minutes after the completion of the infusion for signs and symptoms of a sudden decrease in blood pressure or heart rate (see section 4.4).
Zdravilo BRINAVESS lahko da samo dobro usposobljeno zdravstveno osebje, ki mora pri bolniku med infundiranjem in še vsaj 15 minut po zaključku infundiranja pogosto preveriti, če ima znake in simptome nenadnega znižanja krvnega tlaka ali srčne frekvence (glejte poglavje 4.4).
Instructions on dose calculation, preparation of the solution for infusion, and method of administration.
Navodila za izračun odmerka, pripravo raztopine za infundiranje in način uporabe.
BRINAVESS should be administered by intravenous infusion in a monitored clinical setting appropriate for cardioversion.
Zdravilo BRINAVESS je treba dati v intravenski infuziji v okolju, primernem za kardioverzijo.
- Alert HCP on BRINAVESS contraindications:
- Opozorilo za zdravstveno osebje glede kontraindikacij za zdravilo BRINAVESS:
- Alert HCP about BRINAVESS special warnings and precautions in patients with, clinically meaningful valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis, previously documented LVEF ≤ 35%, advanced hepatic impairment.
- Opozorilo za zdravstveno osebje glede posebnih opozoril in previdnostnih ukrepov za zdravilo BRINAVESS pri bolnikih s klinično pomembno stenozo zaklopk, hipertrofično obstruktivno kardiomiopatijo, restriktivno kardiomiopatijo ali konstriktivnim perikarditisom, predhodno dokumentiranim iztisnim deležem levega prekata (LVEF) ≤ 35 %, z napredovalo okvaro jeter.
• Resumption or initiation of oral-maintenance antiarrhythmic therapy can be considered 2 hours after BRINAVESS administration.
• Ponoven začetek ali uvedba peroralnega vzdrževalnega antiaritmičnega zdravljenja pride v poštev 2 uri po uporabi zdravila BRINAVESS.
• Patients with prolonged QT at baseline (uncorrected > 440 msec), or severe bradycardia, sinus node dysfunction or second degree and third degree heart block in the absence of a pacemaker.
• Bolniki z izhodiščnim podaljšanjem QT (nekorigirani QT > 440 msec) ali s hudo bradikardijo, disfunkcijo sinusnega vozla ali srčnim blokom 2. ali 3. stopnje brez srčnega spodbujevalnika.
- Alert HCP about the need of precautions when using BRINAVESS in haemodynamically stable patients with congestive heart failure NYHA I and NYHA II and the need to monitor patients with valvular heart disease closely.
- Opozorilo za zdravstveno osebje, da je pri uporabi zdravila BRINAVESS pri hemodinamsko stabilnih bolnikih s kongestivnim srčnim popuščanjem v razredih NYHA I in II potrebna previdnost ter da je treba bolnike z boleznijo srčnih zaklopk natančno nadzorovati.
• Use of intravenous rhythm control anti-arrhythmics (class I and class III) within 4 hours prior, as well as in the first 4 hours after, to BRINAVESS administration.
• Uporaba intravenskih antiaritmikov za kontrolo srčnega ritma (skupine I in III) v 4 urah pred uporabo in prve 4 ure po uporabi zdravila BRINAVESS.
• BRINAVESS should be used with caution in patients on oral AADs (class I and III), due to limited experience.
• Zdravilo BRINAVESS je treba pri bolnikih, ki prejemajo peroralne antiaritmike (skupine I in III), zaradi pomanjkanja izkušenj uporabljati previdno.
• BRINAVESS can not be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant, due to lack of data.
• Zdravila BRINAVESS zaradi pomanjkanja podatkov ne moremo priporočiti za bolnike, ki so 4-24 ur pred vernakalantom prejeli intravenski antiaritmik (skupine I in III).
- Alert HCP for use of AADs (anti-arrhythmic drugs) prior to or after BRINAVESS.
- Opozorilo za zdravstveno osebje glede uporabe antiaritmikov pred uporabo zdravila BRINAVESS in po njej.
- Alert HCP for adverse events, which may occur after BRINAVESS administration, including hypotension, bradycardia, atrial flutter, or ventricular arrhythmia.
- Opozorilo za zdravstveno osebje glede neželenih učinkov, ki se lahko pojavijo po uporabi zdravila BRINAVESS, vključno s hipotenzijo, bradikardijo, atrijsko undulacijo ali prekatno motnjo srčnega ritma.
• Intravenous rhythm control AADs should not be used in the first 4 hours after BRINAVESS administration.
• Intravenskih antiaritmikov za kontrolo srčnega ritma se v prvih 4 urah po uporabi zdravila BRINAVESS ne sme uporabljati.
The study lasted six months.
Študija je trajala šest mesecev.
Similar results were seen in the second study after a year.
Podobni rezultati so bili ugotovljeni po enem letu tudi v drugi študiji.
It is available as tablets (80 and 120 mg).
Na voljo je v obliki tablet (80 in 120 mg).
The European Commission granted a marketing authorisation valid throughout the European Union for Adenuric on 21 April 2008.
Evropska komisija je dovoljenje za promet z zdravilom Adenuric, veljavno po vsej Evropski uniji, izdala 21. aprila 2008.
These side effects were mostly mild or moderate in severity.
Ti neželeni učinki so bili večinoma blagi ali zmerni.
The full EPAR for Adenuric can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Adenuric je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
What measures are being taken to ensure the safe and effective use of Adenuric?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Adenuric?
Adenuric should be started two days before chemotherapy and continued for at least 7 days.
Zdravljenje z zdravilom Adenuric je treba začeti dva dni pred kemoterapijo in nadaljevati najmanj sedem dni.
This is a summary of the European public assessment report (EPAR) for Adenuric.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Adenuric.
For more information about treatment with Adenuric, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Adenuric preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The Committee decided that Adenuric's benefits are greater than its risks and recommended that it be given marketing authorisation.
Zato je sklenil, da so koristi zdravila Adenuric večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
A risk management plan has been developed to ensure that Adenuric is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Adenuric je bil pripravljen načrt obvladovanja tveganj.
Other information about Adenuric
Druge informacije o zdravilu Adenuric
In both studies, allopurinol was used at a dose of 300 mg once a day, except in patients with kidney problems, who took 100 mg.
V obeh študijah so alopurinol uporabljali v odmerku 300 mg enkrat dnevno, razen pri bolnikih s težavami z ledvicami, ki so prejemali 100 mg.
Attacks of gout can still occur during the first few months of treatment, so it is recommended that patients take other medicines to prevent attacks of gout for at least the first six months of treatment with Adenuric.
V prvih nekaj mesecih zdravljenja še vedno lahko pride do zagonov protina, zato je priporočljivo, da bolnik vsaj prvih šest mesecev zdravljenja z zdravilom Adenuric jemlje druga zdravila za njihovo preprečevanje.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adenuric.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What benefit has Adenuric shown during the studies?
Kakšne koristi je zdravilo Adenuric izkazalo med študijami?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Adenuric, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Adenuric is a medicine that contains the active substance febuxostat.
Adenuric je zdravilo, ki vsebuje zdravilno učinkovino febuksostat.
For the treatment of hyperuricaemia and gout, Adenuric has been studied in two main studies involving a total of 1,834 patients.
Pri zdravljenju hiperurikemije in protina so učinkovitost zdravila Adenuric proučevali v dveh glavnih študijah, v katerih je sodelovalo skupno 1 834 bolnikov.
Patients received either Adenuric or allopurinol for 7 to 9 days.
Bolniki so sedem do devet dni prejemali bodisi zdravilo Adenuric bodisi alopurinol.
For the treatment of long-term hyperuricaemia, the recommended dose of Adenuric is 80 mg once a day.
Pri zdravljenju dolgotrajne hiperurikemije je priporočeni odmerek zdravila Adenuric 80 mg enkrat na dan.
In patients with blood cancer who were undergoing chemotherapy, Adenuric was as effective as allopurinol in controlling blood levels of uric acid: in 98.3 % of patients (170 out of 173) on Adenuric blood levels of uric acid normalised compared with 96 % (166 out of 173) of patients on allopurinol.
Pri bolnikih s krvnim rakom, ki so prejemali kemoterapijo, je bilo zdravilo Adenuric enako učinkovito kot alopurinol pri uravnavanju ravni sečne kisline v krvi: pri 98,3 % bolnikov (170 bolnikov od 173), ki so prejemali zdravilo Adenuric, se je koncentracija sečne kisline v krvi normalizirala v primerjavi s 96 % bolnikov (166 bolnikov od 173), ki so prejemali alopurinol.
For the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy, Adenuric has been studied in one main study involving 346 adult patients undergoing chemotherapy for blood cancer.
V zvezi s preprečevanjem in zdravljenjem hiperurikemije pri bolnikih, ki prejemajo kemoterapijo, so zdravilo Adenuric proučevali v eni večji študiji, v kateri je sodelovalo 346 odraslih bolnikov, ki so prejemali kemoterapijo za zdravljenje krvnega raka.
The main measure of effectiveness was based on their blood uric acid levels.
Glavno merila učinkovitosti je temeljilo na koncentraciji sečne kisline v krvi.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom mg once a day if blood uric acid levels remain high (above 6 mg per decilitre) after two to four weeks.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom deciliter), odmerek povečati na 120 mg enkrat na dan.